Back to results
US 5,508,276 AGranted
Duloxetine enteric pellets
AssigneesEli Lilly and Company, Shionogi & Co., Ltd.
InventorsNeil R. Anderson, Peter L. Oren, Toshihiro Ogura, Toshiro Fujii
Life of this patent
Estimating the term…
Abstract
A superior enteric formulation of the antidepressant drug, duloxetine, is in the form of enteric pellets of which the enteric layer comprises hydroxypropylmethylcellulose acetate succinate.
Claims18
An enteric duloxetine pellet comprising a) a core consisting of duloxetine and a pharmaceutically acceptable excipient;
- b) an optional separating layer;
- c) an enteric layer comprising hydroxypropylmethylcellulose acetate succinate (HPMCAS) and a pharmaceutically acceptable excipient;
- d) an optional finishing layer.
A process for preparing an enteric duloxetine pellet comprising a) providing a core consisting of duloxetine and a pharmaceutically acceptable excipient;
- b) optionally, applying to the core a separating layer comprising a pharmaceutically acceptable excipient;
- c) applying an enteric layer comprising HPMCAS and a pharmaceutically acceptable excipient, wherein the HPMCAS is supplied as an aqueous solution or suspension and the application takes place in an apparatus of the fluid bed type;
- d) optionally, applying a finishing layer.
Dependencies are inferred from the claim text.